Novo Nordisk is now bidding against competitor Pfizer in an attempt to buy American biotechnology company Metsera. Metsera is dedicated to weight loss and has several drug candidates in development.
Novo Nordisk's share is down 2 percent on the Copenhagen Stock Exchange today. Metsera's share is up 17 percent in American pre-market trading.
